

# In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition<sup>□</sup>

Matthew D. Harwood, Brahim Achour, Sibylle Neuhoff, Matthew R. Russell, Gordon Carlson, Geoffrey Warhurst, and Amin Rostami-Hodjegan

*Gut Barrier Group, Inflammation and Repair, University of Manchester, Salford Royal NHS Trust, Salford, United Kingdom (M.D.H., G.C., G.W.); Simcyp Limited (a Certara company), Blades Enterprise Centre, Sheffield, United Kingdom (M.D.H., S.N., A.R.-H.); and Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, Stopford Building, Manchester, United Kingdom (B.A., M.R.R., A.R.-H.)*

Received October 9, 2015; accepted February 1, 2016

## ABSTRACT

Relative expression factors (REFs) are used to scale in vitro transporter kinetic data via in vitro–in vivo extrapolation linked to physiologically based pharmacokinetic (IVIVE-PBPK) models to clinical observations. Primarily two techniques to quantify transporter protein expression are available, immunoblotting and liquid chromatography–tandem mass spectrometry. Literature-collated REFs ranged from 0.4 to 5.1 and 1.1 to 90 for intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), respectively. The impact of using human jejunum–Caco-2 REFs for P-gp (REF<sub>IP-gp</sub>) and BCRP (REF<sub>IBCRP</sub>), generated from the same samples and using different proteomic methodologies from independent laboratories, on PBPK outcomes was assessed. A 5-fold decrease in REF<sub>IP-gp</sub> for a single oral dose of digoxin resulted in a 1.19- and 1.31-fold higher plasma area under the curve and C<sub>max</sub>, respectively. All generated REF<sub>IP-gp</sub> values

led to simulated digoxin C<sub>max</sub> values within observed ranges; however, combining kinetic data generated from a different laboratory with the 5-fold lower REF<sub>IP-gp</sub> could not recover a digoxin–rifampicin drug–drug interaction, emphasizing the necessity to obtain transporter-specific kinetic estimates and REFs from the same in vitro system. For a theoretical BCRP compound, with absorption taking place primarily in the jejunum, a decrease in the REF<sub>IBCRP</sub> from 2.22 (University of Manchester) to 1.11 (Bertin Pharma) promoted proximal intestinal absorption while delaying t<sub>max</sub> 1.44-fold. Laboratory-specific differences in REF may lead to different IVIVE-PBPK outcomes. To understand the mechanisms underlying projected pharmacokinetic liabilities, it is important to assess the potential impact of bias on the generation of REFs on an interindividual basis within a target population.

## Introduction

In vitro–in vivo extrapolation linked to physiologically based pharmacokinetic (IVIVE-PBPK) models aim to predict profiles of drug disposition dynamically. This is accomplished by incorporating “drug” data, generated in vitro, and physicochemical knowledge together with “systems” data in a population (Rostami-Hodjegan, 2012). Kinetic data [i.e., maximal flux capacity of the transporter protein (J<sub>max</sub>) and K<sub>m</sub>] describing the active transport processes generated from cell systems can also be included in IVIVE-PBPK models. To scale these data to in vivo, human and in vitro system transporter protein expression or activity data are also required in combination with physiologic, demographic, and genetic information (Rostami-Hodjegan, 2012). To date, intestinal transporter IVIVE scaling factors (Neuhoff et al., 2013a) have been generated based on Western blotting, a relative quantitative

technique to quantify transport expression (Troutman and Thakker, 2003b). Yet, absolute transporter protein abundances quantified by liquid chromatography–tandem mass spectrometry (LC-MS/MS) have recently been explored for hepatic application in IVIVE-PBPK (Vildhede et al., 2014).

In this study, we provide a systematic analysis of the mRNA and protein expression data available in the literature for generating the relative expression factor (REF), an IVIVE scalar that describes the ratio of in vivo to in vitro systems transporter expression for human jejunum and Caco-2 monolayer P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). We also evaluate the impact of intestinal P-gp and BCRP REFs generated by different laboratories and methodologies on drug absorption in a PBPK model.

## Materials and Methods

**Literature Review of the Intestinal Expression Data for P-gp and BCRP.** Starting with a previously reported meta-analysis that established human intestinal P-gp and BCRP region-specific protein expression (Harwood et al.,

[dx.doi.org/10.1124/dmd.115.067777](http://dx.doi.org/10.1124/dmd.115.067777).

<sup>□</sup>This article has supplemental material available at [dmd.aspetjournals.org](http://dmd.aspetjournals.org).

**ABBREVIATIONS:** BCRP, breast cancer resistance protein; BPh, Bertin Pharma; DDI, drug–drug interaction; HV, healthy Caucasian volunteer population; IVIVE, in vitro–in vivo extrapolation; LC-MS/MS, liquid chromatography–tandem mass spectrometry; PBPK, physiologically based pharmacokinetic; P-gp, P-glycoprotein; REF, relative expression factor; REF<sub>IBCRP</sub>, intestinal relative expression factor for breast cancer resistance protein; REF<sub>IP-gp</sub>, intestinal relative expression factor for P-glycoprotein; TC, theoretical BCRP compound; UoM, University of Manchester.

2013), a new search for the relevant published data quantifying P-gp and BCRP mRNA or protein expression in human jejunum and filter-grown Caco-2 monolayers using PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) was undertaken. The following keyword combinations were used in PubMed: human; jejunum; Caco-2; P-gp; MDR1; BCRP; ABCB1; ABCG2; mRNA; protein; expression; absolute; abundance; proteomics. Graphical data were extracted, where required, by GetData Graph Digitizer (<http://getdata-graph-digitizer.com>).

**Generation of the Relative Expression Factors.** A REF for P-gp or BCRP was generated, where P-gp or BCRP mRNA/protein expression for human jejunum and Caco-2 monolayers was available using the same technique within a laboratory, including reference genes. These were compared with REFs generated from two different LC-MS/MS workflows (two independent laboratories; matching samples) for P-gp and BCRP in human jejunum and 21-day-cultivated Caco-2 monolayers. Methodological details and individual values are provided in the companion study (Harwood et al., 2016).

**Incorporating Intestinal REFs into IVIVE-PBPK Models.** The impact of the laboratory-specific intestinal relative expression factor for P-glycoprotein ( $REF_{IP-gp}$ ) and intestinal relative expression factor for breast cancer resistance protein ( $REF_{IBCRP}$ ) in virtual healthy Caucasian volunteers (HVs) was assessed in a PBPK model (version 14.1; Simcyp, a Certara company, Sheffield, UK) containing the regional distribution of intestinal P-gp and BCRP and their population variability (Harwood et al., 2013). P-gp and BCRP transport in the model is driven by the unbound intracellular enterocyte concentration and is multiplied by REF and the regional-specific transporter expression to yield effective permeability (Yang et al., 2007; Neuhoff et al., 2013a).

**The Impact of P-gp and BCRP REF in IVIVE-PBPK.** The impact of  $REF_{IP-gp}$  values generated by the LC-MS/MS [University of Manchester (UoM), Manchester, UK; Harwood et al., 2016] compared with the immunoblotting approach (Troutman and Thakker, 2003b) on digoxin  $C_{max}$  was investigated using identical digoxin parameter inputs as the previously reported digoxin IVIVE-PBPK model (Neuhoff et al., 2013a). Caco-2-derived  $J_{max}$  and  $K_m$  data (Troutman and Thakker, 2003a) were applied to intestinal and hepatic P-gp, assuming P-gp activity in vitro in healthy individuals corresponds to that in vivo, and that  $J_{max}$  is related to P-gp protein expression. Simulations were run with a single oral digoxin dose of 0.5 mg in 100 HV individuals to evaluate if kinetic data for digoxin generated in a Caco-2 system from another laboratory (Troutman and Thakker, 2003a) to the  $REF_{IP-gp}$  from the UoM Caco-2 system, could capture the observed digoxin-rifampicin drug-drug interaction (DDI) via induction of intestinal P-gp (Greiner et al., 1999), thus verifying the correct contribution of the active transport built into the digoxin PBPK model.

The impact of laboratory-specific differences for  $REF_{IBCRP}$  on pharmacokinetic parameter predictions was evaluated using the Simcyp simulator. A

permeable theoretical BCRP compound (TC); see (Supplemental Materials, Technical Note with limited gut metabolism and a specific BCRP activity was administered orally (10 mg in solution) to 100 HV individuals, with the default region-specific BCRP expression within the PBPK model, as published by Harwood et al. (2013).

## Results and Discussion

**$REF_{IP-gp}$  and  $REF_{IBCRP}$  Generation from Different Laboratories.** According to our literature analysis, human jejunum mRNA and protein expression was identified in 19 studies for P-gp and nine studies for BCRP [(Supplemental Materials; (Supplemental Table 1)]. Expression data for Caco-2 P-gp and BCRP from the same laboratory using the same protocol to generate an  $REF_{IP-gp}$  or  $REF_{IBCRP}$  were found for five and four studies, respectively (Table 1). For P-gp, relative mRNA expression analysis (reverse-transcription polymerase chain reaction) enabled the generation of  $REF_{IP-gp}$  from two laboratories in three studies (Taipalensuu et al., 2001; Seithel et al., 2006; Hilgendorf et al., 2007), as the data from Seithel et al. (2006) and Hilgendorf et al. (2007) used Caco-2 monolayers cultivated in the same laboratory for 23 and 16 days, respectively. An  $REF_{IP-gp}$  from two independent laboratories that used Western blotting (Troutman and Thakker, 2003b; von Richter et al., 2009) is available, but not for LC-MS/MS quantification for either P-gp or BCRP, as the Caco-2 cell abundances reported by Oswald et al. (2013) were from plastic, not filter-grown cells (Dr. Stefan Oswald, personal communication). The  $REF_{IP-gp}$  based on mRNA expression ranged 7.1-fold, and for LC-MS/MS quantification, 2.6-fold. The  $REF_{IBCRP}$  of 90 (Taipalensuu et al., 2001) may result from low BCRP levels or variability in the housekeeping gene used (Seithel et al., 2006). The  $REF_{IP-gp}$  and  $REF_{IBCRP}$  generated from P-gp and BCRP quantification by LC-MS/MS from two different laboratories, UoM and Bertin Pharma (BPh), for the same samples are provided in Table 1 (Harwood et al., 2016). The  $REF_{IP-gp}$  (Troutman and Thakker, 2003b) from independent samples quantified by Western blotting was 5-fold higher than the  $REF_{IP-gp}$  generated by the UoM (UoM- $REF_{IP-gp}$ ), whereas the UoM- $REF_{IBCRP}$  was approximately 2-fold higher than BPh (LC-MS/MS) and Altana AG (Western blot; Wesel, Germany) (von Richter et al., 2009).

**Assessing the Sensitivity of  $REF_{IP-gp}$  in IVIVE-PBPK.** Both the UoM- $REF_{IP-gp}$  of 0.4 (Harwood et al., 2016) and the  $REF_{IP-gp}$  of 2

TABLE 1

Generation of  $REF_{IP-gp}$  and  $REF_{IBCRP}$  from human jejunum and Caco-2 from relative mRNA expression and protein abundance (relative and absolute) data available in the literature for P-gp (MDR1) and BCRP

Transporter and Method	Reference Standard Gene/Protein/Peptide	Jejunum Abundance Mean (S.D., Sample n)	Caco-2 Abundance Mean (S.D., Sample n)	REF	Source
<b>P-gp (MDR1)</b>					
RT-PCR	Villin	7.90 ( $\pm$ 1.4, n = 13)	11.0 (n = 1)	0.7	Taipalensuu et al., 2001 <sup>a</sup>
RT-PCR	Cyclophilin-A	0.63 ( $\pm$ 0.23, n = 4)	0.13 (n = 1)	5.0	Seithel et al., 2006 <sup>b</sup>
RT-PCR	Cyclophilin-A	1.1 ( $\pm$ 0.67, n=5)	0.21 ( $\pm$ 0.04, n=3 - 6)	5.1	Hilgendorf et al., 2007 <sup>b</sup>
Western blot	Not run in blot	2.12 (n = 1)	1.04 ( $\pm$ 0.16, n = 3)	2.0	Troutman and Thakker, 2003b <sup>c</sup>
Western blot	Not run in blot	1.00 (n = 5, pooled)	1.29 (n = 2)	0.8	Von Richter et al., 2009 <sup>c</sup>
LC-MS/MS	AGAVAEVLAAIR	1.89 ( $\pm$ 1.07, n = 3)	4.67 ( $\pm$ 0.47, n = 3)	0.4	Harwood et al., 2016 <sup>d</sup>
LC-MS/MS	FYDPLAGK	0.77 ( $\pm$ 0.35, n = 3)	2.08 ( $\pm$ 0.19, n = 3)	0.4	Harwood et al., 2016 <sup>e</sup>
<b>BCRP</b>					
RT-PCR	Villin	2.7 ( $\pm$ 1.4, n = 13)	0.03 (n = 1)	90	Taipalensuu et al., 2001 <sup>a</sup>
RT-PCR	Cyclophilin-A	0.38 ( $\pm$ 0.08, n = 4)	0.07 (n = 1)	5.5	Seithel et al., 2006 <sup>b</sup>
RT-PCR	Cyclophilin-A	2.36 ( $\pm$ 0.29, n = 5)	0.36 (n = 3 - 6)	6.6	Hilgendorf et al., 2007 <sup>b</sup>
Western blot	Not run in blot	1.00 (n = 5, pooled)	0.84 (n = 2)	1.2	Von Richter et al., 2009 <sup>c</sup>
LC-MS/MS	VIQELGLDK	(2.56 $\pm$ 0.82, n = 3)	(1.16 $\pm$ 0.04, n = 3)	2.2	Harwood et al., 2016 <sup>d</sup>
LC-MS/MS	SLLDVLAAR	(2.06 $\pm$ 1.11, n = 3)	(1.86 $\pm$ 0.14, n = 3)	1.1	Harwood et al., 2016 <sup>e</sup>

RT-PCR, reverse-transcription polymerase chain reaction.

<sup>a</sup>Units for expression of mRNA are number of transcripts per microgram of total RNA.

<sup>b</sup>Units for expression given as relative units of target to reference gene ( $2^{-\Delta C_t}$ ).

<sup>c</sup>Values for expression given as signal intensity as measured by densitometry image analysis.


<sup>d</sup>Units for abundance given as fmol protein/ $\mu$ g total membrane protein; abundance determined at UoM. The same samples were quantified.

<sup>e</sup>Units for abundance given as fmol protein/ $\mu$ g total membrane protein; abundance determined at BPh. The same samples were quantified.


(Troutman and Thakker, 2003b) led to digoxin  $C_{max}$  values within observed ranges after a single oral dose of 0.5 mg of digoxin (Fig. 1A), implying both  $REF_{IP-gp}$  reflect realistic contributions of P-gp in estimating observed  $C_{max}$  values when using the  $J_{max}$  and  $K_m$  for P-gp reported by Troutman and Thakker (2003a). Using the UoM- $REF_{IP-gp}$  of 0.4 compared with the  $REF_{IP-gp}$  of 2 led to a modest 1.31- and 1.19-fold lower mean  $C_{max}$  and area under the curve, respectively, in 100 HV individuals (Fig. 1B). A previous study showed that the observed digoxin-rifampicin DDI, which was attributed to a 3.5-fold increase in intestinal P-gp expression (Greiner et al., 1999), could be recovered using an IVIVE-PBPK strategy, in which the  $REF_{IP-gp}$  of 2.0 was increased 3.5-fold to 7 after (Fig. 1C) induction (Neuhoff et al., 2013b). A 3.5-fold increase in the UoM- $REF_{IP-gp}$  of 0.4 gave an  $REF_{IP-gp}$  of 1.4, leading to a simulated underprediction in the observed DDI (Fig. 1D). This indicates that the lower UoM- $REF_{IP-gp}$  (that is not derived from the same Caco-2 system in which the apparent kinetic data were generated) is not sufficient to recover the contribution of P-gp induction by rifampicin to digoxin plasma concentration in HVs. The inability to recover the observed DDI when using the UoM- $REF_{IP-gp}$  may result from lower P-gp expression and hence lower activity in the UoM Caco-2 systems. This can be due to laboratory differences in methods of expression quantification, Caco-2 cell cultivation, and the variability in jejunum expression. To recover the activity shortfall when using the UoM- $REF_{IP-gp}$ , a 4.3-fold increase in  $J_{max}$  (1874 pmol/min/cm<sup>2</sup>) was required to recover the observed DDI (Fig. 1E) after using the

Nelder-Mead minimization method and weighted least-squares algorithm in the simulators parameter estimation module (Jamei et al., 2014).

**Assessing the Sensitivity of  $REF_{IBCRP}$  in IVIVE-PBPK.** The sensitivity of the region-specific fraction of dose absorbed and enterocyte concentrations to  $REF_{IBCRP}$  generated by BPh (1.11) and the UoM (2.22) (Table 1; Harwood et al., 2016) was assessed for the BCRP test compound TC. Figure 2 shows the free segmental enterocyte concentration for TC, used as the driving force for apical efflux transporters. As expected, the lower BPh- $REF_{IBCRP}$  leads to higher TC enterocyte concentrations in proximal regions than the higher UoM- $REF_{IBCRP}$ , whereas an increasing importance of intestinal BCRP UoM- $(REF_{IBCRP})$  results in higher TC absorption and higher enterocyte concentration in the distal intestine due to the efflux activity promoting TC retention in the gut lumen and transit to the colon, a region with 7.7-fold lower BCRP levels (Harwood et al., 2013). The higher  $REF_{IBCRP}$  has a limited impact on lowering  $C_{max}$  and area under the curve (1.22- and 1.03-fold, respectively), but increases  $t_{max}$  1.44-fold to 2.8 hours and is in line with clinical observations, where an inhibition of intestinal BCRP leads to a decrease in  $t_{max}$  (Schneck et al., 2004). Alongside differences in BCRP expression, interindividual variability in system parameters, such as the small intestinal transit time (range 0.5–10 hours; Yu et al., 1996), also contributes to region-specific fraction of dose absorbed [Supplemental Fig. 1; (Supplemental Materials)]. Acidic BCRP substrates, such as rosuvastatin, are expected to possess higher enterocyte concentrations, as limited metabolism, low



**Fig. 1.** (A) Sensitivity of  $C_{max}$  to  $REF_{IP-gp}$  for digoxin (single oral dose, 0.5 mg) in 100 HV individuals. The ranges of observed  $C_{max}$  values are given between the dashed lines, and the  $REF_{IP-gp}$  of 2.0 from Troutman and Thakker (2003b) and the UoM- $REF_{IP-gp}$  (Harwood et al., 2016) (dashed arrows) are shown. (B) The mean digoxin plasma concentration when using the  $REF_{IP-gp}$  of 2.0 (Troutman and Thakker, 2003b) and the UoM  $REF_{IP-gp}$  of 0.4 in 100 HVs. The observed and predicted plasma concentrations for digoxin (single oral dose, 1 mg) in 80 HV individuals after the dosing of rifampicin (600 mg, 11 doses, once daily) using an  $REF_{IP-gp}$  of 2 (Troutman and Thakker, 2003b) (C),  $REF_{IP-gp}$  of 0.4 (Harwood et al., 2016) (D), and  $REF_{IP-gp}$  of 0.4 (E) after optimizing the  $J_{max}$  of P-gp by parameter estimation. The thin gray lines represent mean values for 10 individual virtual trials of eight individuals, males aged 21–37 years; the thick black lines are the overall means of the virtual population ( $n = 80$ ); and the dashed gray lines are the 95th and 5th percentiles of the confidence interval. Open circles mark the observed digoxin concentrations when coadministered with multiple doses of rifampicin (Greiner et al., 1999).



**Fig. 2.** Simulated enterocyte concentration profiles for all intestinal segments of the model for the BCRP compound TC (10 mg oral, single dose, in solution) in 100 HVs using the BPh  $REF_{IBCRP}$  (1.11) or UoM- $REF_{IBCRP}$  (2.22) with a mean small intestinal transit time of 3.34 hours, a passive apparent permeability of  $115.2 \times 10^{-6}$  cm/s, and an intrinsic clearance for BCRP of  $17 \mu\text{l}/\text{min}/\text{cm}^2$ .

passive permeation, and apical uptake transporters operate (Li et al., 2012; Jamei et al., 2014). Therefore, increased BCRP expression alters  $t_{\text{max}}$  and regional absorption, while not limiting overall absorption and bioavailability. This is dissimilar to the cooperation of P-gp and CYP3A4 activities that facilitate a drug's repeated exposure to intestinal CYP3A4, increasing overall gut metabolism and reducing bioavailability (Wacher et al., 1998). To our knowledge, the current study is the first highlighting this difference of the colocalized transporters P-gp and BCRP.

Combining IVIVE scalars and activity data generated from different laboratories for ATP-dependent transporters may not lead to successful IVIVE, whereas we postulate that laboratory-specific differences in REF may impact the mechanistic understanding of projected pharmacokinetic liabilities (efficacy/toxicity). This is due to in vitro activity, reproducibility of in vitro assays, culture conditions, and proteomic workflows. As discussed previously, direct translation of protein expression to activity may not always occur; therefore, accounting for deviations in this linear relationship via activity-abundance scalars will be required (Harwood et al., 2013). Ideally, scaling factors should be defined on a laboratory-specific basis against a common reference and combined with activity data from the same system. However, it is improbable within an industrial setting that groups will possess a bank of human intestinal tissues by which to obtain the in vivo abundance for

in-house intestinal REF generation. It is therefore advocated that commercially available pooled human intestinal microsomes (constituting  $\geq 20$  intestines) are used to generate an REF using the same proteomic methods as those used for quantifying in vitro system abundances used for determining activity. Alternatively, a link between human liver microsomes, intestinal microsomes, and Caco-2 cells can be approached.

#### Authorship Contributions

*Participated in research design:* Harwood, Neuhoff, Warhurst, Rostami-Hodjegan.

*Conducted experiments:* Harwood, Achour.

*Contributed new reagents or analytic tools:* Russell, Carlson.

*Performed data analysis:* Harwood, Achour, Neuhoff.

*Wrote or contributed to the writing of the manuscript:* Harwood, Achour, Neuhoff, Warhurst, Rostami-Hodjegan.

#### References

- Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J Clin Invest* **104**:147–153.
- Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G and Rostami-Hodjegan A (2016). In vitro-in vivo extrapolation scaling factors for intestinal P-glycoprotein and breast cancer resistance protein: Part I: A cross-laboratory comparison of transporter protein

- abundances and relative expression factors in human intestine and Caco-2 cells. *Drug Metab Dispos* **44**:297–307.
- Harwood MD, Neuhoff S, Carlson GL, Warhurst G, and Rostami-Hodjegan A (2013) Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. *Biopharm Drug Dispos* **34**:2–28.
- Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab Dispos* **35**:1333–1340.
- Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. *Clin Pharmacokinet* **53**:73–87.
- Li J, Wang Y, Zhang W, Huang Y, Hein K, and Hidalgo IJ (2012) The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. *Drug Metab Dispos* **40**:2102–2108.
- Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, and Rostami-Hodjegan A (2013a) Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. *J Pharm Sci* **102**:3145–3160.
- Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, and Rostami-Hodjegan A (2013b) Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. *J Pharm Sci* **102**:3161–3173.
- Oswald S, Gröer C, Drozdik M, and Siegmund W (2013) Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters. *AAPS J* **15**:1128–1140.
- Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clin Pharmacol Ther* **92**:50–61.
- Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CDA, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clin Pharmacol Ther* **75**:455–463.
- Seithel A, Karlsson J, Hilgendorf C, Björquist A, and Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. *Eur J Pharm Sci* **28**:291–299.
- Taipalensuu J, Tömbblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. *J Pharmacol Exp Ther* **299**:164–170.
- Troutman MD and Thakker DR (2003a) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. *Pharm Res* **20**:1200–1209.
- Troutman MD and Thakker DR (2003b) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. *Pharm Res* **20**:1210–1224.
- Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Norén A, and Artursson P (2014) Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. *Drug Metab Dispos* **42**:1210–1218.
- von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, and Zech K (2009) A novel screening strategy to identify ABCB1 substrates and inhibitors. *Naunyn Schmiedebergs Arch Pharmacol* **379**:11–26.
- Wacher VJ, Silverman JA, Zhang Y, and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. *J Pharm Sci* **87**:1322–1330.
- Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. *Curr Drug Metab* **8**:676–684.
- Yu LX, Crison JR, and Amidon GL (1996) Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. *Int J Pharm* **140**:111–118.

---

**Address correspondence to:** Dr. Matthew D. Harwood, Simcyp Ltd. (a Certara company), Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK. E-mail: matthew.harwood@certara.com

---